Suppr超能文献

淋巴管浸润作为三阴性乳腺癌术后的不良预后因素。

Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery.

作者信息

Ahn Ki Jung, Park Jisun, Choi Yunseon

机构信息

Department of Radiation Oncology, Inje University Busan Paik Hospital, Busan, Korea.

Department of Nuclear Medicine, Inje University Busan Paik Hospital, Busan, Korea.

出版信息

Radiat Oncol J. 2017 Dec;35(4):332-339. doi: 10.3857/roj.2017.00416. Epub 2017 Dec 15.

Abstract

PURPOSE

This study aimed to evaluate the prognostic effects of lymphovascular invasion (LVI) in triple-negative breast cancer (TNBC) patients who underwent surgical resection.

MATERIALS AND METHODS

A total of 63 non-metastatic TNBC patients who underwent surgical resection were retrospectively investigated from 2007 to 2016 in Inje University Busan Paik Hospital. Pathological tests revealed that 12 patients (19.0%) had LVI. Approximately 61.9% (n = 39) of the patients' samples stained positive for p53. Additional chemotherapy and radiotherapy (RT) were performed in 53 (84.1%) and 47 (74.6%) patients, respectively.

RESULTS

The median follow-up period was 39.5 months (range, 5.9 to 123.0 months). The pathological T stage (p = 0.008), N stage (p = 0.014), and p53 positivity (p = 0.044) were associated with LVI. Overall, the 3-year disease-free survival (DFS) rate and overall survival (OS) rate were 85.4% and 90.2%, respectively. Ten patients (15.9%) experienced relapse. LVI (n = 12) was associated with relapses (p = 0.016). p53 positivity was correlated with poor DFS (p = 0.048). Furthermore, LVI was related to poor DFS (p = 0.011) and OS (p = 0.001) and considered as an independent prognostic factor for DFS (p = 0.039). The 3-year DFS of patients with LVI (n = 12) was only 58.3%. Adjuvant RT minimized the negative prognostic effect of LVI on DFS (p = 0.068 [with RT] vs. p = 0.011 [without RT]).

CONCLUSION

LVI was related to the detrimental effects of disease progression and survival of TNBC patients. Thus, a more effective treatment strategy is needed for TNBC patients with LVI.

摘要

目的

本研究旨在评估接受手术切除的三阴性乳腺癌(TNBC)患者中淋巴管侵犯(LVI)的预后影响。

材料与方法

回顾性调查了2007年至2016年在仁济大学釜山白医院接受手术切除的63例非转移性TNBC患者。病理检查显示,12例患者(19.0%)存在LVI。约61.9%(n = 39)的患者样本p53染色呈阳性。分别有53例(84.1%)和47例(74.6%)患者接受了辅助化疗和放疗。

结果

中位随访期为39.5个月(范围为5.9至123.0个月)。病理T分期(p = 0.008)、N分期(p = 0.014)和p53阳性(p = 0.044)与LVI相关。总体而言,3年无病生存率(DFS)和总生存率(OS)分别为85.4%和90.2%。10例患者(15.9%)出现复发。LVI(n = 12)与复发相关(p = 0.016)。p53阳性与DFS较差相关(p = 0.048)。此外,LVI与DFS较差(p = 0.011)和OS较差(p = 0.001)相关,并被视为DFS的独立预后因素(p = 0.039)。LVI患者(n = 12)的3年DFS仅为58.3%。辅助放疗将LVI对DFS的负面预后影响降至最低(p = 0.068[放疗组]对p = 0.011[未放疗组])。

结论

LVI与TNBC患者疾病进展和生存的不良影响相关。因此,对于存在LVI的TNBC患者需要更有效的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f59/5769883/3a5ccd3657c7/roj-2017-00416f1.jpg

相似文献

1
Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery.
Radiat Oncol J. 2017 Dec;35(4):332-339. doi: 10.3857/roj.2017.00416. Epub 2017 Dec 15.
7
The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer.
J Breast Cancer. 2011 Sep;14(3):198-203. doi: 10.4048/jbc.2011.14.3.198. Epub 2011 Sep 29.
8
The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer.
Med J Islam Repub Iran. 2022 Jun 8;36:61. doi: 10.47176/mjiri.36.61. eCollection 2022.
10
Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Breast. 2015 Dec;24(6):723-31. doi: 10.1016/j.breast.2015.09.001. Epub 2015 Sep 19.

引用本文的文献

3
Clinical Characteristics and Management of Triple-Negative Breast Cancer (TNBC) in Jordan: A Retrospective Analysis.
Cureus. 2024 Jan 27;16(1):e53053. doi: 10.7759/cureus.53053. eCollection 2024 Jan.
5
Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay.
Histol Histopathol. 2024 Feb;39(2):177-200. doi: 10.14670/HH-18-655. Epub 2023 Jul 31.
9
Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
Breast Cancer. 2022 Jan;29(1):164-173. doi: 10.1007/s12282-021-01294-1. Epub 2021 Sep 16.
10
Utility of post mastectomy radiotherapy among patients with T1/ T2 N1 disease: A retrospective cohort study.
Ann Med Surg (Lond). 2021 Apr 16;65:102295. doi: 10.1016/j.amsu.2021.102295. eCollection 2021 May.

本文引用的文献

1
Tailoring radiotherapy according to cancer subtypes.
Breast. 2017 Aug;34 Suppl 1:S91-S94. doi: 10.1016/j.breast.2017.06.036. Epub 2017 Jun 30.
3
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Cancer Biol Ther. 2017 Jun 3;18(6):369-378. doi: 10.1080/15384047.2017.1323582. Epub 2017 May 11.
6
Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2016 Jun;157(3):555-64. doi: 10.1007/s10549-016-3837-5. Epub 2016 May 25.
8
Breast cancer intrinsic subtype classification, clinical use and future trends.
Am J Cancer Res. 2015 Sep 15;5(10):2929-43. eCollection 2015.
9
High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer.
Mol Clin Oncol. 2015 Sep;3(5):1103-1108. doi: 10.3892/mco.2015.574. Epub 2015 Jun 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验